ECOR1 CAPITAL, LLC
ECOR1 CAPITAL, LLC is a Pre-seed, Seed, Series A, Series B and Series C+ fund in the US and Global writing $1M–$50M checks into Healthcare and biotechnology.
- Stages
- Pre-seed, Seed, Series A, Series B, Series C+
- Sectors
- Healthcare, biotechnology
- Check size
- $1M–$50M
- Invests in
- US-wide, Global
- Round role
- Leads rounds
- Actively investing
- Yes
- Founded
- 2012
- Assets under management
- $5B
Thesis
ECOR1 CAPITAL, LLC is a biotechnology-focused investment firm founded in 2012. Their investment thesis centers on companies developing novel therapeutics for untreated diseases, emphasizing scientific rigor, management quality, and patient outcomes. They partner with entrepreneurs to advance therapeutic innovation, offering strategic support beyond capital. The firm invests across all stages, from pre-seed to pre-IPO, with a global geographic scope and a strong emphasis on North America. Their typical check size ranges from $1 million to $50 million, and they have a propensity for lead investments. As of March 2024, ECOR1 CAPITAL manages approximately $5 billion in AUM. The firm manages various funds, including those investing in public and private biotech companies, as well as those focused solely on privately held global biotechnology companies. In December 2024, the firm and Nodelman were fined by the French financial markets regulator for share price manipulation.
Common questions
Does ECOR1 CAPITAL, LLC invest at the Pre-seed stage?
Yes. ECOR1 CAPITAL, LLC lists Pre-seed, Seed, Series A, Series B and Series C+ among the stages it invests in.
What check size does ECOR1 CAPITAL, LLC write?
ECOR1 CAPITAL, LLC writes $1M–$50M checks.
Where does ECOR1 CAPITAL, LLC invest?
ECOR1 CAPITAL, LLC invests in the US and Global.